Replies to post #87004 on Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

well spoken - my exact point - we've been prostituted to the PIPE's and every other financial gypsie, vagabond and financial warlock that exists Downtown. Upon initiation of the 1st major financial milestone/agreement, lets overhaul the CFO division as we move uptown - please. I'm leary at best with this Marc E. Faerber character - his finger on the financial pulse of the corporation and past performance is disconcerting - I'm uncomfortable - there's better out there - much much better! Look at the backgrounds of the BOD and the Corp. Advisors - then compare why we are dealing with someone who only has a BS in Accounting and an inactive CPA license:

Pfizer, Amgen, Novartis, Bristol Myers Squibb, McKesson Corp., SuperGen, Cetus Corp., Aurora Biosciences, Ascenta Therapeutics, Elan Pharma. - Wharton Business School, Columbia, Princeton, Yale, Tufts, Rockefeller Univ. - American Medical Foundation, Goldman Sachs, Bridge Clinical Research Inst., NINDSNIH, etc. etc. etc.

Dr. Joseph Rubinfeld

* Amarantus BioSci., BOD
* Amgen, Co-founder
* Bristol Myers Squibb, SSOP
* Cetus Corp., Sr. Dir.
* SuperGen, Co-founder, Pres. & CEO
* Inventor - Amoxicillin
* Inventor - Biodegradable Detergent
* Inventor - Polaroid Instimatic Film
* Columbia Univ., PhD Chemistry

Dr. Adam J. Simon

* Amarantus BioSci., BOD
* AJ Simon Enterprises, LLC - Pres. & CEO
* Cerora, Inc. - Pres. & CEO
* Merck Research Labs - Sr. Research Fellow
* Princeton Univ. - Academic BOD
* SUNY Rochester, NY - BS Physics & Mathematics
* University of Chicago - Phd. Physics
* Holds four patents related to medical research, and has
* Publisher of 60 Scientific & Medical Journal articles

Owen Garrick, MD MBA

* Amarantus BioSci., BOD
* Bridge Clinical Research, Pres. & COO
* AMA Foundation, Pres.
* McKesson Corp., Dir. Corp. Strategy & Business Devl.
* Novartis, Co-Head M&A's
* Goldman Sachs, Associate
* Yale School of Medicine, MD
* Wharton School of Business, MBA
* Princeton Univ., AB
* Princeton Univ., BOD - Natl. Fund Raising Bd.

Mark Benedyk, PhD

* Amarantus BioSci., BOD
* Rila Partners LLC, Managing Partner
* Center for Drug R&D Ventures Inc., Dir.
* CNS Regenerative Medicine Found., BOD Trans. Medicine Advisory
* The Pfizer Incubator (TPI), Dir.
* The Pfizer Incubator (TPI), Portfolio Seat - Investments
* Ascenta Therapeutics, Business Devl.
* Optimer Biotech., Business Devl.
* Aurora BioSci., aka Vertex Pharma., Business Devl.
* Elan Pharma., Business Devl.
* The Rockefeller Univ., PhD, Developmental Genetics
* Stanford Univ., MBA
* Univ. of Virginia Darden School of Business, Grad. Cert.
* Univ. of Michigan, BS, Microbiology & BS, Botany

Clinton Allen, MSc

* Amarantus BioSci., BOD
* Bristol Myers Squibb, Dir. Corp. Compliance Audit
* Bristol Myers Squibb, Sr. Dir. Risk Management
* Bristol Myers Squibb, Dir. Prod. Devel. & Commercialization
* Bristol Myers Squibb, Dir. In-licensing & Business Devel.
* Tufts Univ., MSc. Environmental Mngt. & Sciences
* Capitan, US Army

Colin Bier, MD

http://www.biomedreports.com/20130903150913/amarantus-appoints-dr.-colin-bier-to-advisory-board-for-lympro-commercialization.html

John W. Commissiong, MD, Phd.

* Amarantus BioSci., Founder
* Chief Scientific Officer Director of Jumpkicks Inc. 2000 - 2008
* CSO of Neurotrophics Inc
* C0-fonder of Prescient Neuropharma Inc.
* Head of the Neurotrophic Factors Group NINDSNIH from 1994-1997
* Chief of Neural Transplantation Unit NINDSNIH from 1989-1994
* Discoverer of MANF - 2003
* USNHI - Director

Steven Gill - MB, FRCS, MS

* Performing the study to compare MANF and GDNF

http://www.spirehealthcare.com/bristol/our-facilities-treatments-and-consultants/our-consultants/professor-steven-gill/